Influence of Maternal Preeclampsia on Neurodevelopmental Outcomes of Preterm Infants

Halil DEGIRMENCIOGLU, Birgul SAY, Zeynep ERAS, Serife Suna OGUZ
Aydın, Turkey

ABSTRACT

OBJECTIVE: The aim of this study was to determine the neurodevelopmental outcome of preterm infants born to mothers with preeclampsia and to compare them with preterm controls.

STUDY DESIGN: This was a retrospective, observational study in a large, tertiary, neonatal intensive care unit. Neurodevelopmental evaluations using Bayley Scales of Infant Development II were performed in 226 two-year-old infants with birth weight ≤1500 g and gestational age ≤32 weeks who were born to mothers with preeclampsia and in 493 infants who were born after normotensive pregnancies, matched for gestational age and gender.

RESULTS: The mean gestational ages of the infants in the preeclampsia and control groups were 29.9±2.3 weeks and 28.7±4.1 weeks, respectively (p<0.001). A total of 372 infants with a mean age of 19.2±3.2 months were assessed for long-term outcome. The mean mental developmental index score was significantly higher, and the percentage of infants with cerebral palsy was significantly lower, in the preeclampsia group compared with the control group (p=0.03 and p=0.02, respectively). However, no overall significant differences in neurodevelopmental impairment rates were found between the two groups (p=0.08).

CONCLUSION: Maternal preeclampsia seems to be a protector factor for the development of cerebral palsy in preterm infants.

Keywords: Preeclampsia, Neurodevelopmental outcome, Preterm infant

Gynecol Obstet Reprod Med 2018;24(2):99-103

Introduction

In recent decades, advances in perinatal and neonatal care have led to an improved survival rate among preterm infants. However, the rates of major short- and long-term morbidities have not changed (1). Several prenatal (preeclampsia, gestational diabetes, choioamnionitis) and postnatal (respiratory distress syndrome (RDS), sepsis, patent ductus arteriosus (PDA), necrotizing enterocolitis (NEC), intraventricular hemorrhage (IVH), bronchopulmonary dysplasia (BPD) factors have been linked to impaired neurodevelopment outcome (2,3).

Recent available data on long-term outcomes in preterm infants exposed to preeclampsia in utero are highly variable (7). Some studies demonstrated that preeclampsia has a great impact on mental developmental (4,8), while other studies suggested that infants born to preeclamptic mothers had higher developmental testing scores at 18 months corrected age (9) and a decreased risk of cerebral palsy (5). These data obviously indicate that conflicting results regarding adverse neurodevelopmental outcome in infants exposed to maternal preeclampsia still exist. Therefore, we conducted a retrospective case–control study to evaluate both short- and long-term outcomes in infants (birth weight ≤1500 g and gestational age...
≤32 weeks) born to mothers with preeclampsia and in infants born to control mothers, regardless of exposure to magnesium sulfate during pregnancy.

**Material and Method**

**Study Population**

This retrospective, single-center study was conducted in the neonatal intensive care unit of Zekai Tahir Burak Maternity Teaching Hospital, Ankara, Turkey, from January 2008 to November 2013. All preterm infants with a gestational age ≤32 weeks and birth weight ≤1500 g born to mothers with preeclampsia without any other coexisting medical conditions were included and compared with infants born after normotensive pregnancies and matched for gestation, gender, and survival. Subjects with other maternal conditions affecting neurological outcome, such as chorioamnionitis, death, prolonged rupture of membranes, diabetes mellitus, intrauterine growth retardation and infants with major congenital malformations, were excluded from the study.

Two groups were defined: i) infants exposed to maternal preeclampsia (study group) and ii) control infants born to normotensive mothers and matched for gestational age and gender. The medical records of both mothers and newborns, including parental, medical, demographic, and obstetric details, were extracted from the hospital records by the researchers.

Preeclampsia was defined as blood pressure 140/90 mmHg accompanied by proteinuria level ≥300 mg/24 h after 20 weeks of gestation (3). Gestational age was evaluated by maternal dates and confirmed by the modified Ballard examination (10).

Neurodevelopmental outcomes at 18 to 24 months' corrected age were evaluated with neurologic exams and Bayley Scales of Infant Development II. A comprehensive evaluation, including neurological examination, vision and hearing examination, and developmental assessment using Bayley Scales of Infant Development II, were performed by experienced examiners.

Written informed consent for the study was obtained from a parent or guardian of each infant, and the study protocol was approved by the local ethics committee of Zekai Tahir Burak Maternity Teaching Hospital.

**Definition of outcome variables**

Neurodevelopmental impairment (NDI) was defined as the presence of one or more of the following events: (1) cerebral palsy (CP) with functional deficits, (2) bilateral hearing loss and/or blindness, and (11) mental developmental index (MDI) and/or psychomotor developmental index (PDI) <70 (>2 standard deviations below a mean of 100). CP was defined as a non-progressive motor disorder with abnormal muscle tone in at least one extremity and abnormal control of movement and posture (12). Infants who were severely impaired and not able to complete the test were assigned an MDI or PDI score of 49.

**Statistical analysis**

A descriptive analysis of the demographic and clinical characteristics of the patients was conducted. Student’s t-test or the Mann-Whitney U test was used for comparison of numeric variables between the two groups. The chi-square test was used to compare ratios between the two groups. Binary logistic regression analysis was used to conduct a multivariate analysis of factors associated with neurodevelopmental outcome. The statistical analyses were performed with SPSS software version 17.0 (SPSS Inc., Chicago, IL), and statistical significance was set at \( p < 0.05 \).

**RESULTS**

**Baseline characteristics**

Between March 2008 and January 2012, 1120 infants were assessed for eligibility in the trial. A total of 719 infants met the inclusion criteria. The study group consisted of 226 premature infants born to mothers with preeclampsia, and the control group consisted of 493 preterm infants born to normotensive mothers. Figure 1 shows the flow chart for the study group. Baseline demographic characteristics of the groups are summarized in table 1. Mean gestational age of the infants in the preeclampsia and control groups were 29.9 ± 2.3 weeks and 28.7 ± 4.1 weeks, respectively; the difference was statistically significant (\( p < 0.001 \)). The mean birth weights did not differ significantly between the groups (1117 ± 267 g and 1121 ± 296 g, respectively; \( p = 0.8 \).
No significant differences were found between the two groups in postnatal risk factors such as low Apgar score, duration of mechanical ventilation, RDS, PDA, severe IVH, hypoglycemia, polycythemia, and BPD.

**Neurodevelopmental outcomes**

During the study period, 106 (47%) of the 226 infants in the preeclampsia group and 242 (49%) of the 493 infants in the control group were excluded due to incomplete follow-up, refusal to participate, or relocation. A total of 371 premature infants were assessed at 18-24 months CA for the neurodevelopmental. Of those patients, 120 were in the preeclampsia group and 251 were in the control group. Neurodevelopmental assessment was performed at a mean age of 19.2±3.2 months CA.

**Table 1: Baseline characteristics of infants**

<table>
<thead>
<tr>
<th>Variable</th>
<th>PE (n = 226)</th>
<th>No PE (n = 493)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gestational age, weeksa</td>
<td>29.9±2.3</td>
<td>28.7±4.1</td>
<td>p&lt;0.001</td>
</tr>
<tr>
<td>Birth weight, g²</td>
<td>1117±267</td>
<td>1121±296</td>
<td>0.80</td>
</tr>
<tr>
<td>Gender (male)b</td>
<td>101 (44)</td>
<td>290 (59)</td>
<td>0.12</td>
</tr>
<tr>
<td>Low Apgar score (5 min &lt;5)b</td>
<td>34 (15)</td>
<td>79 (16)</td>
<td>0.08</td>
</tr>
<tr>
<td>Duration of mechanical ventilation (days)a</td>
<td>5.3±10</td>
<td>6.2±16</td>
<td>0.4</td>
</tr>
<tr>
<td>RDS, use of surfactantb</td>
<td>129 (57)</td>
<td>245 (49)</td>
<td>0.12</td>
</tr>
<tr>
<td>PDAa</td>
<td>51 (22)</td>
<td>134 (25)</td>
<td>0.27</td>
</tr>
<tr>
<td>Severe IVH, n</td>
<td>6</td>
<td>14</td>
<td>0.18</td>
</tr>
<tr>
<td>Hypoglycemia, n</td>
<td>13</td>
<td>25</td>
<td>0.1</td>
</tr>
<tr>
<td>Polycythemia, n</td>
<td>26</td>
<td>50</td>
<td>0.1</td>
</tr>
<tr>
<td>BPD, n</td>
<td>24</td>
<td>51</td>
<td>0.618</td>
</tr>
</tbody>
</table>

*a: Mean ± SD, b: n (%), c: Severe was defined as grade 3 or 4 intraventricular hemorrhage using the criteria of Papile15, RDS: Respiratory distress syndrome, PDA: Patent ductus arteriosus, BPD: Bronchopulmonary dysplasia*

**Table 2: Analysis of neurodevelopmental outcomes at 18–24 months corrected age (CA)**

<table>
<thead>
<tr>
<th>Variables</th>
<th>PE (n = 120)</th>
<th>No PE (n = 251)</th>
<th>p*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Birth weight, g²</td>
<td>1124±228</td>
<td>1124±253</td>
<td>0.06</td>
</tr>
<tr>
<td>Gestational age, weeka</td>
<td>29.6±1.9</td>
<td>29.2±1.8</td>
<td>0.93</td>
</tr>
<tr>
<td>Asphyxia, n</td>
<td>0</td>
<td>2</td>
<td>0.45</td>
</tr>
<tr>
<td>Sepsisb</td>
<td>58 (48)</td>
<td>125 (49.8)</td>
<td>0.42</td>
</tr>
<tr>
<td>Hypothyroidismb</td>
<td>5 (0.04)</td>
<td>16 (0.06)</td>
<td>0.27</td>
</tr>
<tr>
<td>IVH, Grade 3-4, n</td>
<td>3</td>
<td>10</td>
<td>0.44</td>
</tr>
<tr>
<td>NEC, Stage 3-4, n</td>
<td>0</td>
<td>6</td>
<td>0.05</td>
</tr>
</tbody>
</table>

**Neurodevelopmental Outcomes**

<table>
<thead>
<tr>
<th>NDId</th>
<th>102 (59.3)</th>
<th>102 (59.3)</th>
<th>0.08</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDI²</td>
<td>89.7±19.7</td>
<td>84.6±21.6</td>
<td>0.03</td>
</tr>
<tr>
<td>PDI²</td>
<td>84.6±20.6</td>
<td>82.4±21.9</td>
<td>0.35</td>
</tr>
<tr>
<td>MDI &lt; 70b</td>
<td>25 (21)</td>
<td>65 (26)</td>
<td>0.29</td>
</tr>
<tr>
<td>PDI &lt; 70b</td>
<td>36 (30)</td>
<td>76 (30)</td>
<td>0.36</td>
</tr>
<tr>
<td>CP, n</td>
<td>7</td>
<td>34</td>
<td>0.02</td>
</tr>
<tr>
<td>Bilateral deafness, n</td>
<td>0</td>
<td>1</td>
<td>0.52</td>
</tr>
<tr>
<td>Bilateral blindness, n</td>
<td>0</td>
<td>0</td>
<td>-</td>
</tr>
</tbody>
</table>

*a: Mean ± SD, b: n (%), PE: Preeclampsia, IVH: Intraventricular hemorrhage, NEC: Necrotizing enterocolitis, NDI: Neurodevelopmental impairment, MDI: Mental developmental index, PDI: Psychomotor developmental index, CP: Cerebral palsy*

Data of the demographic and neurodevelopmental outcomes at two years of age are shown in table 2. No significant differences were found between the groups in variables such as gestational age, birth weight, asphyxia, sepsis, hypothyroidism, severe IVH, and severe NEC.

The preeclampsia group had significantly higher MDI scores (89.7±19.7) compared to the control group (84.6±21.6) (*p=0.03*). The mean PDI scores were 84.6±20.6 in the preeclampsia group and 82.4±21.9 in the control group; the difference was not significant (*p=0.35*). Cerebral palsy was present in seven (6%) of the 120 infants in the preeclampsia group and in 34 (14%) of the 251 infants in the control group; the preeclampsia group had a significantly lower rate.
(p=0.02). This difference was confirmed in the multiple logistic regression model; in which it was found that preeclampsia was a possible factor protecting the infants from CP (OR=0.39; 95% confidence interval (CI): 0.17-0.91). Overall, however, no statistically significant difference in NDI was found between the groups (p=0.08), confirmed by multiple logistic regression analysis (OR=1.44; CI: 0.91-2.27).

**Discussion**

In this study, we report on a relatively large study population with long-term data of approximately 50% of the surviving infants of both groups. The results of this study suggested that maternal preeclampsia might have a positive impact on the neurodevelopmental outcome of preterm infants.

Maternal preeclampsia seems to be a protector factor for the development of cerebral palsy in preterm infants, (8). Preeclampsia is not a uniform disease, and it can range from a subacute or chronic course to acute disease with sudden deterioration of the placenta–fetal blood supply. Although the hemodynamic effects of preeclampsia can be partly reduced by fetal compensatory mechanisms, even moderate preeclampsia exposes the fetus to placental insufficiency, which can lead to intrauterine ischemic brain damage (3).

Studies on the outcome of infants born to mothers with preeclampsia have yielded conflicting results. Some studies have suggested that maternal preeclampsia is associated with significant developmental delays in gross motor, fine motor, and visual motor functions in early childhood (13,14). Taylor et al. found strong associations between all categories of disability, with the exception of CP, and severe hypertension or preeclampsia during pregnancy (15). Szymonowicz and Yu found that the developmental index at the age of two years was not different, but that the mean MDI was significantly lower and the incidence of CP was higher in infants born to mothers with preeclampsia (16). Many et al. reported that newborns born after pregnancies complicated by preeclampsia have lower IQs at three years of age compared to babies born to mothers without preeclampsia (13). In a study conducted in Sweden, preeclampsia was associated with a high risk of CP (OR 1.5, 95% CI 1.3-2.4) (17).

Some studies have suggested that preeclampsia has no negative impact on long-term outcomes. Seidman et al. found no differences between the IQ scores of infants born to mothers with and without preeclampsia (18). Schlapbach et al. compared the neurodevelopmental outcomes of infants born at <32 weeks’ gestational age after maternal preeclampsia or chorioamnionitis and those of controls, and they concluded that chorioamnionitis and preeclampsia exposure were not associated with major neurodevelopmental impairments (CP, MDI <70, PDI <70) (20).

Some evidence suggests that preeclampsia is associated with a decreased risk of CP. Gray et al. found that maternal preeclampsia has a protective effect on CP in infants born at ≤32 weeks’ gestation, regardless of exposure to magnesium sulfate (21). Xiong et al. performed a meta-analysis and reported that preeclampsia was associated with a statistically significantly decreased risk of CP in preterm and low birth weight infants [pooled adjusted OR=0.50; 95% CI: 0.33-0.81; p<0.01]. Silveira et al. reported better neurodevelopment outcomes at 18 months CA in infants delivered by preeclamptic mothers than in controls (9).

In our study, although overall NDI rates did not differ significantly between the two groups, MDI scores were higher and CP rates were lower in the preeclampsia group. The odds of CP for preterm infants, was 0.39 times lower with preeclampsia present than without, which is similar to results found in other analyses (21,22,23).

The potential causes of such differences are not clear. One possible explanation is that the cumulative in utero and postnatal factors probably have a higher impact on these high-risk infants. Secondly, we already know that antenatal maternal treatment with magnesium sulfate can improve the neurodevelopmental outcomes of premature infants (23,24). However, because mothers with high-risk pregnancies are routinely supplemented with magnesium sulfate in our hospital, we could not assess the extent to which this factor affected outcome.

One of our limitations is that the study is not recorded in the treatment of mothers with preeclampsia (Mg, etc.) and the other one is the small sample size.

In conclusion, we also observed a nonsignificant association between preeclampsia and developmental delay and neurodevelopmental impairment in very low birth weight preterm infants. Longer term neurodevelopmental outcomes for prematurely born infants are dependent on gestational age. Further studies are needed to confirm this continuous relationship between neurodevelopmental outcomes and preeclampsia.

**Acknowledgments:** This study was conducted by the Zekai Tahir Burak Maternity Teaching Hospital Neonatology Department and Blood Center Department. H.D., B.S., and Z.U. made substantial contributions to the study design and data collection, as well as critically revising the manuscript. S.S.O., supported the data collection and critically revised the manuscript.

**Conflict of Interest:** The authors have no competing interests.

**Funding:** No foundation

**References**

22. Xiong X, Saunders LD, Wang FL, Davidge ST, Buekens P. Preeclampsia and cerebral palsy in low-birth-weight and preterm infants: implications for the current “ischemic